Enterprise Value

294.6M

Cash

119.2M

Avg Qtr Burn

-26.18M

Short % of Float

6.10%

Insider Ownership

17.36%

Institutional Own.

61.20%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Bota-vec (Botaretigene sparoparvovec) (AAV-RPGR) Details
X-linked retinitis pigmentosa, Genetic disorder, Eye disease

Phase 3

Update

AAV-RPE65 Details
Eye disease , Retinal dystrophy

Phase 3

Initiation

AAV-CNGB3 Details
Achromatopsia, Genetic disorder, Autosomal recessive congenital ichthyosis , Skin disease/disorder

Phase 2b

Update

AAV-CNGA3 Details
Achromatopsia

Phase 2b

Update

AAV-hAQP1 Details
Salivary gland

Phase 2

Data readout

AAV-GAD Details
Parkinson's disease

Phase 2

Update